Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Zoetis    ZTS

ZOETIS

(ZTS)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Zoetis : Says EC Grants Marketing Authorization for Antiparasitic Medication for Dogs

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/20/2019 | 09:55am EDT

By Michael Dabaie

Zoetis Inc. (ZTS) said the European Commission granted marketing authorization for Simparica Trio chewable tablets, a once-monthly triple combination antiparasitic medication for dogs.

The marketing authorization follows a positive opinion adopted by the Committee for Medicinal Products for Veterinary Use in July.

Zoetis said it expects to launch Simparica Trio in the EU in the first quarter of 2020.

Shares were up about 1% in early trading.

Write to Michael Dabaie at michael.dabaie@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZOETIS
10/22ZOETIS : to Participate in the Credit Suisse 28th Annual Healthcare Conference
BU
10/16A DAY IN THE LIFE : Delivering Great Customer Experiences
PU
10/03ZOETIS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
AQ
10/03ZOETIS : Declares Fourth Quarter 2019 Dividend
BU
10/03KRISTIN PECK : Zoetis Names Kristin Peck Chief Executive
DJ
10/03ZOETIS INC. : Change in Directors or Principal Officers, Other Events, Financial..
AQ
10/03ZOETIS : Names Kristin Peck to Succeed Juan Ramón Alaix as CEO on January 1, 202..
BU
10/01ZOETIS : Insigniam Quarterly Features Interview with Kristin Peck
PU
10/01ZOETIS : Simparica Trio™, a Once-Monthly Triple Combination Antiparasitic ..
AQ
09/30ZOETIS : to Host Webcast and Conference Call on Third Quarter 2019 Financial Res..
BU
More news
Financials (USD)
Sales 2019 6 237 M
EBIT 2019 2 314 M
Net income 2019 1 411 M
Debt 2019 4 112 M
Yield 2019 0,50%
P/E ratio 2019 41,8x
P/E ratio 2020 33,7x
EV / Sales2019 10,1x
EV / Sales2020 9,28x
Capitalization 58 649 M
Chart ZOETIS
Duration : Period :
Zoetis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZOETIS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 132,19  $
Last Close Price 122,81  $
Spread / Highest target 18,1%
Spread / Average Target 7,64%
Spread / Lowest Target -30,8%
EPS Revisions
Managers
NameTitle
Juan Ramón Alaix Chief Executive Officer & Director
Mike B. McCallister Non-Executive Chairman
Glenn C. David Chief Financial Officer & Executive Vice President
Catherine Ann Knupp Executive VP, President-Research & Development
Andrew Fenton Chief Digital & Technology Officer, Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
ZOETIS43.57%58 649
ELANCO ANIMAL HEALTH INCORPORATED-17.41%9 713
DECHRA PHARMACEUTICALS22.90%3 377
JINYU BIO-TECHNOLOGY CO., LTD.49.34%3 087
VIRBAC91.56%2 047
PULIKE BIOLOGICAL ENGINEERING, INC.59.36%952